Entegrion to develop blood product for U.S. Navy

08/26/2011 | MedCityNews.com

North Carolina biotech firm Entegrion is set to receive $9.84 million from the Navy for the development of a single blood product that has the potential to save lives on the battlefield. The product will combine two experimental blood products: Resusix, a freeze-dried human plasma designed to serve as an alternative to fresh-frozen plasma, and Stasix, a freeze-dried product based on blood platelets.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO